Chronic myeloid leukemia reminiscences and dreams by Tariq

Chronic myeloid leukemia: reminiscences and dreams by Tariq I. Mughal, Jerald P. Radich, Michael W. Deininger, Jane F. Apperley, Timothy P. Hughes, Christine J. Harrison, Carlo Gambacorti-Passerini, Giuseppe Saglio, Jorge Cortes, and George Q. Daley haematol Volume 101(5): 541 -558 April 30, 2016 © 2016 by Ferrata Storti Foundation

Survival with chronic myeloid leukemia over time (1993– 2013): the German CML-Study Group experience. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Janet Rowley and John Goldman. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Milestones in the study and treatment of chronic myeloid leukemia. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Detection of the t(9; 22)(q 34; q 11) chromosomal translocation. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

The structure of the normal BCR and ABL 1 genes and the fusion transcripts found in Ph-positive leukemias. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Cytoplasmic BCR-ABL 1 activates a myriad of signal pathways. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Imatinib binds an Inactive ABL 1 conformation. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Definitions of response. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Mutations in the kinase domain of ABL 1 identified in tyrosine kinase inhibitors (TKI) resistant chronic myeloid leukemia cells. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Chemical structures of imatinib, nilotinib, dasatinib, bosutinib and ponatinib. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Adverse events related to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

DASISION and ENESTnd: summary of data from different studies. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Chronic myeloid leukemia survival after allo-stem cell transplantation. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

Targeting chronic myeloid leukemia cells at different levels. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation

European Leukemia. Net 2013 Guidelines: response to first-line treatment with imatinib, nilotinib or dasatinib. Tariq I. Mughal et al. Haematologica 2016; 101: 541 -558 © 2016 by Ferrata Storti Foundation